Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Streptococcal M protein is the primary virulence factor of Group A Streptococcus (GAS), a Gram-positive bacterium responsible for a wide range of human diseases. It is a fibrillar, coiled-coil surface protein that extends from the bacterial cell wall and exhibits significant sequence variability, particularly in its N-terminal region, leading to over 200 known emm types (UniProt P02977; StatPearls: Group A Streptococcus). The protein's main biological role is to facilitate immune evasion by inhibiting phagocytosis; it achieves this by binding host complement regulators like Factor H and C4b-binding protein, as well as fibrinogen, which masks the bacteria from the host's immune system (Nature Reviews Microbiology: Virulence factors of Group A Streptococcus; PubMed: M protein and complement evasion). Beyond immune evasion, M protein acts as an adhesin, helping the bacteria attach to host epithelial cells during the initial stages of infection (StatPearls: Group A Streptococcus). In clinical contexts, M protein is a major driver of post-streptococcal sequelae, such as acute rheumatic fever, due to molecular mimicry where antibodies against certain M protein epitopes cross-react with human tissues like cardiac myosin (AHA Journals: Rheumatic Fever and M protein). Consequently, it is a central target for vaccine development, though the risk of inducing autoimmunity and the high degree of antigenic variation remain significant therapeutic challenges (WHO: GAS vaccine development technology roadmap). Current research focuses on identifying conserved regions of the protein to create broadly protective vaccines that avoid cross-reactive epitopes (Nature Reviews Microbiology).
Vaccine candidates and therapeutic antibodies target the M protein to induce opsonization and phagocytosis of the bacteria, while also neutralizing its ability to bind complement inhibitors and fibrinogen (Nature Reviews Microbiology; WHO).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcal M protein (M protein) (M protein).